Physician profile
Matthew Jacobsen
NPI 1003913138
$3,156.39
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $393 · 2021: $640 · 2022: $792 · 2023: $808 · 2024: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.78 | 2021-2024 | |
| Allergan, INC. | $301.86 | 2019-2020 | |
| Novo Nordisk INC | $292.41 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $255.79 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.36 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $133.50 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $121.70 | 2019-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $96.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.23 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $61.75 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $47.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $46.02 | 2021-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $43.96 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $38.88 | 2023 | Optimizer |
| Adlon Therapeutics L.P. | $27.46 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.25 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $24.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2023 | Rexulti |
| Mylan Specialty L.P. | $20.05 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.57 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.06 | 2022 | |
| Genentech USA, INC. | $17.02 | 2019 | |
| Boston Scientific Corporation | $16.84 | 2024 | Watchman Flx |
| Medtronic, INC. | $15.31 | 2023 | Kyphon Express II Kyphopak Tray |
| Stryker Corporation | $13.90 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.49 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $13.47 | 2022 | |
| Amgen INC. | $13.30 | 2023 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jacobsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.